Adagio Therapeutics annonce une réduction de l’activité neutralisante in vitro de l’ADG20 contre le variant Omicron du virus SARS-CoV-2

Les données in vitro précédemment rapportées démontrant que les mutations Omicron individuelles n’étaient pas associées à l’échappement de l’ADG20 ne se traduisent pas par des essais Omicron sur des souches authentiques et des pseudovirus

WALTHAM, Mass., 14 déc. 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc. (Nasdaq : ADGI), une société biopharmaceutique au stade clinique axée sur la découverte, le développement et la commercialisation de solutions à base d’anticorps pour les maladies infectieuses présentant un potentiel pandémique, a fait aujourd’hui le point suite à des analyses in vitro externes visant à évaluer l’activité neutralisante de l’ADG20 contre le variant Omicron du SARS-CoV-2. Les données in vitro générées par le biais de tests effectués à la fois sur des souches authentiques et des pseudovirus du variant Omicron montrent une réduction de plus de 300 fois de l’activité neutralisante de l’ADG20 contre Omicron. Des analyses supplémentaires sont en cours, et la société prévoit de collaborer avec les agences gouvernementales et de réglementation afin d’évaluer le rôle que l’ADG20 peut jouer dans la prévention et le traitement de la COVID-19, en particulier alors que se développe la compréhension du secteur quant à l’épidémiologie et l’impact d’Omicron et des nouveaux variants potentiels.

« En raison de la nature hautement conservée et immunorécessive de l’épitope reconnu par l’ADG20, nous prévoyons que l’ADG20 devrait conserver son activité neutralisante contre Omicron, conformément à l’activité observée dans les modèles in vitro avec tous les autres variants préoccupants connus », a déclaré Tillman Gerngross, Ph.D., président-directeur général d’Adagio. « Bien que les mutations individuelles au niveau du domaine de fixation au récepteur Omicron n’aient pas été associées à un échappement de l’ADG20 dans le contexte d’une souche originale du virus, de nouvelles données montrent que la combinaison des mutations présentes dans la protéine Spike d’Omicron a entraîné une réduction de la neutralisation de l’ADG20 non suggérée par des données antérieures. La prévalence continue du variant Delta aux États-Unis et dans d’autres pays, l’évolution des variants du SARS-CoV-2 et les futurs coronavirus potentiels impliquent la nécessité d’une multitude de traitements et d’approches. Grâce à une équipe d’experts déterminés à faire progresser les solutions d’anticorps qui luttent contre cette pandémie sans précédent et à un bilan solide, nous menons des analyses supplémentaires afin d’évaluer la voie optimale à suivre avec l’ADG20 en tant qu’option prophylactique et de traitement de la COVID-19. »

L’ADG20 est un produit candidat expérimental à base d’anticorps monoclonal (mAb) conçu pour fournir une activité neutralisante large et puissante contre le SARS-CoV-2, y compris les variants préoccupants, pour la prévention et le traitement de la COVID-19 avec une durée potentielle de protection pouvant aller jusqu’à un an avec une seule injection. Dans les études in vitro précédemment divulguées, l’ADG20 a conservé son activité par rapport aux variants préoccupants antérieurs, y compris Alpha, Bêta, Delta et Gamma. Par ailleurs, de nouvelles données in vitro ont démontré une activité neutralisante conservée de l’ADG20 contre un panel diversifié de variants circulants du SARS-CoV-2, y compris les variants Lambda, Mu et Delta plus. L’innocuité et l’efficacité de l’ADG20 n’ont pas été établies, et aucun pays n’a autorisé ni approuvé l’utilisation de l’ADG20.

Adagio évalue actuellement l’ADG20 dans le cadre d’essais cliniques mondiaux de phase 2/3 à la fois pour la prévention et le traitement de la COVID-19. Sur la base des résultats in vitro liés à Omicron, Adagio prévoit de suspendre le recrutement des patients dans son essai de phase 2/3 sur le traitement de la COVID-19 dans des sites cliniques en Afrique du Sud, où Omicron a émergé en tant que variant dominant. Adagio est en train d’évaluer les prochaines étapes de son programme ADG20.

Des analyses in vitro ont également été menées sur l’ADG10, un deuxième mAb en développement, qui ont montré une activité neutralisante minimale contre le variant Omicron dans les essais de neutralisation des souches authentiques et des pseudovirus.

À propos d’Adagio Therapeutics
Adagio (Nasdaq : ADGI) est une société biopharmaceutique au stade clinique axée sur la découverte, le développement et la commercialisation de solutions à base d’anticorps pour les maladies infectieuses présentant un potentiel pandémique, y compris la COVID-19 et la grippe. Le portefeuille d’anticorps de la société a été optimisé grâce aux capacités de pointe d’Adimab en matière d’ingénierie d’anticorps et est conçu pour fournir aux patients et aux cliniciens une combinaison potentielle inégalée de puissance, d’ampleur, de protection durable (grâce à l’extension de la demi-vie), de faisabilité de fabrication et de prix abordable. Le portefeuille d’anticorps contre le SARS-CoV-2 d’Adagio comprend plusieurs anticorps fortement neutralisants non concurrents dotés d’épitopes de liaison distincts, dirigés par l’ADG20. Adagio a conclu avec des sous-traitants tiers un contrat portant sur des capacités de fabrication pour la production de l’ADG20 afin de soutenir l’achèvement des essais cliniques et le lancement commercial initial, garantissant ainsi une large accessibilité potentielle aux populations du monde entier. Pour plus d’informations, rendez-vous sur notre site www.adagiotx.com.

Énoncés prospectifs
Le présent communiqué de presse contient des énoncés prospectifs au sens de la loi Private Securities Litigation Reform (Réforme sur la résolution des litiges portant sur des titres privés) de 1995. Des mots tels que « anticipe », « croit », « s’attend à », « a l’intention de », « prévoit » et « à l’avenir » ou des expressions similaires sont destinés à identifier des énoncés prospectifs. Les énoncés prospectifs comprennent les énoncés concernant, entre autres choses, le calendrier, les progrès et les résultats de nos études précliniques et des essais cliniques sur l’ADG20, y compris le calendrier des futures mises à jour du programme et le lancement, la modification et l’achèvement des études ou des essais et travaux préparatoires connexes, la période au cours de laquelle les résultats des essais seront disponibles et nos programmes de recherche et développement ; les analyses supplémentaires et en cours pour évaluer l’activité de l’ADG20 par rapport au variant Omicron et le potentiel de l’ADG20 à jouer un rôle à la fois en tant qu’option prophylactique et option de traitement pour la COVID-19 ; le profil risque/bénéfice de nos produits candidats pour les patients ; et l’adéquation de notre trésorerie, équivalents de trésorerie et titres négociables. Il se peut que nous ne soyons effectivement pas en mesure d’atteindre les plans, les intentions ou les attentes divulgués dans nos énoncés prospectifs, et vous ne devez pas vous fier indûment à nos énoncés prospectifs. Ces énoncés prospectifs impliquent des risques et des incertitudes qui pourraient amener nos résultats réels à différer sensiblement des résultats décrits ou sous-entendus par les énoncés prospectifs, y compris, sans limitation, les impacts de la pandémie de COVID-19 sur nos activités, essais cliniques et situation financière, les données d’innocuité ou d’efficacité inattendues observées lors d’études précliniques ou d’essais cliniques, les taux d’activation ou de recrutement de site d’essai clinique qui sont inférieurs aux prévisions, l’évolution de la concurrence attendue ou existante, les changements dans l’environnement réglementaire, et les incertitudes et le calendrier du processus d’approbation réglementaire. D’autres facteurs pouvant causer une différence matérielle entre nos résultats réels et ceux exprimés ou sous-entendus dans les énoncés prospectifs de ce communiqué de presse sont décrits sous la rubrique « Risk Factors » (Facteurs de risque) du rapport trimestriel d’Adagio sur le formulaire 10-Q pour le trimestre clos le 30 septembre 2021 et dans les futurs rapports qu’Adagio déposera auprès de la SEC. De tels risques peuvent être amplifiés par les impacts de la pandémie de COVID-19. Les énoncés prospectifs contenus dans le présent communiqué de presse sont formulés à cette date, et Adagio décline toute obligation de mettre à jour ces informations sauf si la loi en vigueur l’exige.

Contacts:
Media Contact: Investor Contact:
Dan Budwick, 1AB Monique Allaire, THRUST Strategic Communications
Dan@1abmedia.com monique@thrustsc.com

Casio to Release G-SHOCK Collaboration Models with the TV documentary series Matchday: Inside FC Barcelona

TOKYO, Dec. 15, 2021 /PRNewswire/ — Casio Computer Co., Ltd. announced today the latest additions to its G-SHOCK brand of shock-resistant watches. The GBD-H1000BAR and GBD-100BAR are collaboration models celebrating Matchday: Inside FC Barcelona, a documentary featuring the inner world of the famed Spanish football club.

GBD-H1000BAR (left), GBD-100BAR (right)

The base models for the two new watches are the GBD-H1000 and GBD-100, both from the G-SQUAD line. The new models employ the blue and garnet team colors of FC Barcelona. The bands, designed to evoke past and present team uniforms, are imprinted with the club motto, “Més que un club” (“More than a club”) in the local Catalan language. The GBD-H1000BAR features a metal bezel in bright gold ion plating that shines like a winners’ trophy cup, while the band loop on both watches features the four red stripes of the Catalan flag. Specially designed packaging also in FC Barcelona team colors is a final touch worthy of these singular timepieces.

GBD-H1000BAR / GBD-100BAR

Both new watches are equipped with an accelerometer to count steps and track distances. The GBD-H1000BAR also comes with a heart rate monitor and GPS tracking. Both new models also offer mobile link functions which, when paired with a dedicated smartphone app, support daily health management by allowing users to check life logs with data on step counts and calories burned, activity logs, and more. The Memory in Pixel (MIP) LCD display for exceptional visibility and the soft urethane band for outstanding ventilation and flexibility deliver comfort in every situation, from everyday use to hard workouts.

Special packaging (GBD-H1000BAR [left]; GBD-100BAR [right])

Matchday: Inside FC Barcelona

An eight-episode documentary series focusing on the 2018–2019 season of one the world’s most adored football clubs. From the thrill of victory to the agony of defeat, the series offers insight into the players, philosophy and culture of FC Barcelona.

Photo – https://mma.prnewswire.com/media/1708036/image_1.jpg
Photo – https://mma.prnewswire.com/media/1708149/image_2.jpg
Photo – https://mma.prnewswire.com/media/1708038/image_3.jpg

Adagio Therapeutics Relata Redução na Atividade Neutralizante In Vitro do ADG20 Contra a Variante Omicron SARS-CoV-2

Dados in vitro relatados anteriormente que demonstram que as mutações individuais do Omicron não estavam associadas à fuga de ADG20 não se confirmam nos ensaios autênticos de Omicron e de Pseudovírus

WALTHAM, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) — A Adagio Therapeutics, Inc., (Nasdaq: ADGI) uma empresa biofarmacêutica de estágio clínico focada na descoberta, desenvolvimento e comercialização de soluções com base em anticorpos para combate de doenças infecciosas com potencial pandêmico, divulgou novas informações após uma análise in vitro externa da atividade neutralizante do ADG20 da variante Omicron SARS-CoV-2. Os dados in vitro gerados através de testes autênticos e de pseudovírus da variante Omicron mostram uma redução de mais de 300 vezes na atividade neutralizante do ADG20 do Omicron. Análises adicionais estão sendo realizadas e a empresa pretende se envolver com agências reguladoras e governamentais para avaliar o papel que o ADG20 pode desempenhar na prevenção e tratamento da COVID-19, particularmente diante de mais compreensão por parte da indústria quanto à epidemiologia e o impacto doa Omicron e de possíveis novas variantes.

“Devido à natureza altamente conservada e imunorecessiva do epítopo reconhecido pelo ADG20, previmos que o ADG20 reteria a atividade neutralizante do Omicron, de acordo com a atividade observada em modelos in vitro com todas as outras variantes preocupantes conhecidas”, disse Tillman Gerngross, Ph.D., diretor executivo da Adagio. “Embora as mutações individuais presentes no domínio de ligação ao receptor Omicron não tenham sido associadas à fuga do ADG20 no contexto de uma cepa original do vírus, novos dados mostram que a combinação de mutações presentes na proteína de pico do Omicron levou a uma redução na neutralização do ADG20 não indicada pelos dados anteriores. A prevalência contínua da variante Delta nos EUA e em outros países, a evolução das variantes do SARS-CoV-2 e o potencial futuro coronavírus fazem necessárias uma infinidade de terapias e abordagens. Com uma equipe de especialistas comprometida com o avanço das soluções de anticorpos que combatem essa pandemia sem precedentes e um forte balanço patrimonial, estamos realizando análises adicionais para avaliar o caminho ideal a seguir com o ADG20 como uma opção profilática e de tratamento para a COVID-19.”

O ADG20 é um candidato a produto de anticorpo monoclonal (mAb) investigacional criado para fornecer atividade neutralizante ampla e potente do SARS-CoV-2, incluindo das variantes preocupantes, para a prevenção e tratamento da COVID-19. Em estudos in vitro divulgados anteriormente, o ADG20 manteve a atividade contra variantes preocupantes anteriores, incluindo Alfa, Beta, Delta e Gama. Recentes dados in vitro demonstraram a atividade neutralizante retida do ADG20 contra um painel diversificado de variantes circulantes de SARS-CoV-2, incluindo as recém-surgidas variantes Lambda, Mu e Delta plus. A segurança e a eficácia do ADG20 não foram estabelecidas e o ADG20 não está autorizado ou aprovado para uso em nenhum país.

A Adagio está avaliando o ADG20 em estudos clínicos globais de Fase 2/3 para a prevenção e tratamento da COVID-19. Com base nos resultados in vitro relacionadas ao Omicron, a Adagio pretende interromper o recrutamento de pacientes para o seu estudo de tratamento de Fase 2/3 COVID-19 em locais clínicos na África do Sul, onde o Omicron emergiu como a variante dominante. A Adagio está avaliando os próximos passos para seu programa ADG20.

Análises in vitro também foram conduzidas com o ADG10, um segundo mAb em desenvolvimento, que demonstrou atividade neutralizante mínima da variante Omicron em ensaios de neutralização autênticos e de pseudovírus.

Sobre a Adagio Therapeutics
A Adagio (Nasdaq: ADGI) é uma empresa biofarmacêutica de estágio clínico focada na descoberta, desenvolvimento e comercialização de soluções com base em anticorpos para o tratamento de doenças infecciosas com potencial pandêmico, inclusive COVID-19 e gripe. O portfólio de anticorpos da empresa foi otimizado com os recursos de engenharia de anticorpos líderes da indústria da Adimab, e foi criado para fornecer aos pacientes e médicos o potencial para uma combinação de potência, amplitude, proteção durável (via extensão de meia-vida), capacidade de fabricação e acessibilidade. O portfólio de anticorpos contra SARS-CoV-2 da Adagio inclui múltiplos anticorpos amplamente neutralizantes não competitivos com epítopos de ligação distintos, liderados por ADG20. A Adagio adquiriu a capacidade de fabricação para a produção do ADG20 com fabricantes terceirizados para apoiar a conclusão de ensaios clínicos e lançamento comercial inicial, garantindo o potencial para o amplo acesso para as pessoas em todo o mundo. Para mais informação, visite www.adagiotx.com.

Declarações de Previsão
Este comunicado para a imprensa contém declarações consideradas declarações de previsão de acordo com o Private Securities Litigation Reform Act of 1995. Palavras como “antecipa”, “acredita”, “espera”, “pretende”, “projeta”, e “futura”, e expressões similares são usadas para identificar declarações de previsão. As declarações de previsão incluem declarações sobre, entre outras coisas, a ocasião, progresso e resultados dos nossos estudos pré-clínicos e ensaios clínicos do ADG20, incluindo a ocasião das atualizações futuras do programa e a iniciação, modificação e conclusão de estudos ou ensaios e trabalhos preparatórios relacionados, o período durante o qual os resultados dos ensaios estarão disponíveis, e nossos programas de pesquisa e desenvolvimento; as análises adicionais e contínuas para avaliar a atividade do ADG20 contra a variante Omicron e o potencial do ADG20 de desempenhar um papel como uma opção profilática e de tratamento para a COVID-19; o perfil de risco/benefício dos nossos candidatos a produtos para os pacientes; e a adequação do nosso caixa, equivalentes de caixa e valores mobiliários negociáveis. Podemos não atingir os planos, intenções ou expectativas mencionadas nas nossas declarações de previsão, e você não deve depositar confiança indevida nas nossas declarações de previsão. Essas declarações de previsão envolvem riscos e incertezas que podem fazer com que nossos resultados reais sejam substancialmente diferentes dos resultados descritos ou implícitos nas declarações de previsão, incluindo, sem limitação, os impactos da pandemia de COVID-19 nos nossos negócios, ensaios clínicos e posição financeira, dados inesperados de segurança ou eficácia observados durante estudos pré-clínicos ou ensaios clínicos, taxas de ativação ou inscrição no local de ensaios clínicos inferiores ao esperado, mudanças na concorrência esperada ou existente, mudanças no ambiente regulatório e as incertezas e o momento do processo de aprovação regulatória. Outros fatores que podem fazer com que nossos resultados reais sejam substancialmente diferentes dos resultados descritos ou implícitos nas declarações de previsão neste comunicado para a imprensa, descritos no título “Fatores de Risco” no prospecto da Adagio arquivado na Comissão de Valores Mobiliários (“SEC”) no Formulário 10-Q do trimestre encerrado em 30 de setembro de 2021, e nos relatórios futuros da Adagio a serem arquivados no SEC. Tais riscos podem ser amplificados pelos impactos da pandemia de COVID-19. As declarações de previsão contidas neste comunicado para a imprensa são válidas a partir desta data, e a Adagio não se compromete a atualizar essas informações, exceto se exigido por lei.

Contatos:
Contato com a Mídia: Contato com o Investidor:
Dan Budwick, 1AB Monique Allaire, THRUST Strategic Communications
Dan@1abmedia.com monique@thrustsc.com

Next Ocean Youth and Sports Commission Games to add academic component proposed by Seychelles

For the first time since its inception over 25 years ago, the Ocean Youth and Sport Commission Games – in French, La Commission de la Jeunesse et des Sports e l’Ocean Indien (CJSOI) — will feature an academic component alongside the traditional cultural exchanges and sporting events.

Seychelles’ minister for Youth, Sports and Family, Marie Celine Zialor, who is the current president of the CJSOI, proposed the idea. It was endorsed during a working mission to Mauritius from December 8-13, where the secretariat of the CJSOI is based and where the 12th edition of the games is to be held in December 2022.

Zialor told SNA she and her counterpart in Mauritiius, Minister Stephan Toussaint, discussed the Blue Economy concept together.

“Blue economy is crucial and important for both island nations and its huge potentials must be understood by young people of our islands,” said Zialor. The two ministers agreed that as island nations the Blue Economy should be a strong component of the 12th edition of the games.

Training and conference will be part of activities earmarked for the youth component of the games which brings together young people aged 14 to 17.

The academic component will consist of leadership training, exchanges involving young professionals within the sector as well as conferences on opportunities and potentials for professional development, careers and entrepreneurship amongst other topics within the blue economy.

These will be held during the games or leading up to the games, as the modality is yet to be decided.

The CJSOI Games which are held every two years were introduced in 1994 by the Ministerial Committee of the Commission de la Jeunesse et des Sports de l’Ocean Indien. Its objectives are to promote friendship ties between young people from member States and foster regional cooperation, sporting culture and development of young people.

The member states of CJSOI include the Comoros, Djibouti, Madagascar, Mauritius, Mayotte, Reunion Island and Seychelles, a group of 115 islands in the western Indian Ocean.

Zialor said that young people being future leaders should be included in discussions on the Blue Economy, something she said is needed as Indian Ocean nations can be the leaders in this sector, adding that both islands have huge exclusive economic zones (EEZ).

Toussaint on his part welcomed what he described as an excellent proposition as he said the two nations have big economic exclusive zones, adding that already Seychelles and Mauritius have joint management of the Mascarene Plateau.

“The potential for cooperation is there, especially when we share a common maritime area. We are going to set up a structure to work on this project,” added Toussaint.

The Mauritian Minister explained that it is time for young people to move away from traditional fields for career development and see what exists for professions within the Blue Economy.

The two ministers also talked about other ways to renew and increase areas of cooperation in sports – especially water sports – but also in other fields that affect youth such as youth development in entrepreneurship, health and the Blue Economy.

Source: Seychelles News Agency

Beyond2020 Enhances Water Access for 18,000 Filipinos in Upland Rural Areas

Beyond2020 returns to Southeast Asia following key sustainable engagements in Indonesia and Cambodia, with a deployment that is uplifting the lives of 18,000 people in The Philippines by enhancing water access and reducing water costs by 85%. Four hydraulic ram pumps and 13 kiosks are being used to impact 3,000 residents in the village of Cabagnaan in the Province of Negros Occidental and 15,000 people in 14 villages across Altavista in the Province of Leyte.

The innovative technology is an enhancement of a system created more than 240 years ago that brings water uphill without the use of electricity or fuel and the emission of harmful gasses.

Launched by the Zayed Sustainability Prize in partnership with several leading organisations, the Beyond2020 initiative exemplifies the humanitarian legacy of the UAE’s founding father, the late Sheikh Zayed bin Sultan Al Nahyan by donating sustainable technologies and solutions to vulnerable communities worldwide. The Philippines marks the tenth deployment of Beyond2020, which effectively addresses some of the world’s most pressing sustainable development challenges, providing quality healthcare, nutritious food, essential energy, and access to safe water for drinking and sanitation.

H.E. Mohammed Obaid Al Zaabi, UAE Ambassador to the Philippines, said: “As a wide-reaching humanitarian initiative spearheaded by the UAE government and its wise leadership to drive sustainable economic growth globally, Beyond2020 offers crucial and life-transforming solutions to beneficiaries worldwide. The initiative’s deployment in the Philippines offers communities innovative water technology solutions that aim to improve the health and wellbeing of rural residents through long-term impact, paving the way for an easier, safer and more sustainable lifestyle.”

H.E. Al Zaabi added, “The UAE and the Philippines share a common vision towards building a more prosperous and sustainable future for their people, in accordance with the UN’s Sustainable Development Goals. Moreover, the collaboration complements our historically close bilateral relations across multiple avenues. By tackling water scarcity, the drive to further optimise a vital resource for the benefit of communities in the Philippines, also coincides with the recent launch of the UAE’s ‘Principles of the 50’ that seek to stimulate socio-economic growth through humanitarian aid. They are important guiding principles inspired by the enduring legacy of the UAE’s founding father, the late Sheikh Zayed, based on his core values of sustainability, humanitarianism and global cooperation.”

The communities of Cabagnaan and Altavista, that are located on different islands, share the same challenges, whereby water is not available and has to be fetched from a source located further downhill from the community. The deployment utilises a holistic ram pump water system by the Alternative Indigenous Development Foundation, Inc. (AIDFI), a 2020 Zayed Sustainability Prize finalist under the ‘Water’ category.

The Philippines Ambassador to the UAE, H.E. Hjayceelyn M. Quintana added, “We are pleased to see the introduction of these essential, environmentally-friendly and life-changing solutions by the Beyond2020 initiative. The notable reach and impact of the technology supports the Philippine government’s drive to improve public services and the health of our citizens, with water being a key priority for social welfare and sustainable development.”

“We are confident that the mobilsation of international action that empowers and supports our communities’ ability to access and manage water resources will promote widespread benefits to the daily lives of impacted beneficiaries. We therefore extend our gratitude to the initiative and its partners whose involvement has been central to the realisation of the project on the ground today.”

H.E. Ólafur Grímsson, Chair of the Zayed Sustainability Prize Jury and former President of the Republic of Iceland, said, “Beyond2020’s latest project in the Philippines demonstrates the power of leveraging an innovative solution by our global community of winners and finalists and exploring its long-term capacity for beneficiaries. The initiative also demonstrates the power of collaboration as the Prize and its partners have impacted communities in 10 countries to-date, with further deployments scheduled for 2022.”

In addition to providing clean water for drinking and sanitation, the carbon-neutral technology offers residents the opportunity to improve or pursue water-related livelihoods such as vegetable gardens, aquaculture, and livestock breeding, while facilitating a more conducive environment to avoid several waterborne diseases stemming from dirty water. Furthermore, access to improved hygiene grows in prominence given the importance of handwashing in preventing the spread of COVID-19, a pressing concern for vulnerable communities worldwide.

Ten deployments have been rolled out to date under the umbrella of Beyond2020, with another nine in progress. Completed deployments include vital energy, health, water and food-related solutions in Nepal, Tanzania, Uganda, Jordan, Egypt, Cambodia, Madagascar, Indonesia, Bangladesh, and The Philippines.

Beyond2020 brings together a leading number of partners which include Abu Dhabi Fund for Development, Mubadala Petroleum and Masdar.

Source: Business Wire

Stay Calm, Don’t Panic, Says South African Doctor

The head of the South African Medical Association says there is a major difference between the delta and omicron variants of the coronavirus and warns politicians against hyping the threat from the new strain.

Dr. Angelique Coetzee criticized Tuesday what she described as the “over-reaction” to the heavily mutated omicron variant by some European governments and cited Britain’s Boris Johnson, who she accused of creating “hysteria” about the new strain.

On Tuesday, the House of Commons approved the reimposition of pandemic restrictions, and the introduction of some new ones, because of rising omicron cases in the country, although Johnson faced a major rebellion by a third of his parliamentary party and relied on opposition parties for the vote.

Coetzee was one of the first medical practitioners in the world to raise the alarm about the new variant. Its genomic data was sequenced last month by scientists in Hong Kong, Botswana as well as South Africa. The emergence has contributed to pandemic alarm in Europe, where governments are already battling the delta strain and are racing to reimpose restrictions.

Coetzee told Britain’s Sky News that delta was heart-breaking and that her patients who contracted it were “extremely, extremely sick” and when opening the door to them “you just knew they were in trouble,” she explained.

But nearly a month into the omicron wave in South Africa, she says she has not seen similar grim scenes and that her omicron patients are suffering much milder symptoms. Apart from one, who had HIV and other comorbidities, none have died.

The British government’s medical advisers are predicting one million omicron infections by the end of the month, and although South Africa is seeing tens of thousands of new cases daily.

Coetzee cautions calm, saying Britain and other European countries are much better vaccinated than South Africa and in a better position to battle it. “Even if you get breakthrough infections, it’s mild cases,” she added, saying she understands the need to take precautionary measures but says, “don’t hype it up.”

Some scientists disagree with Coetzee.

The chief executive of Britain’s Health Security Agency told lawmakers Wednesday that omicron “is probably the most significant threat since the start of the pandemic.”

Dr. Jenny Harries said the new variant was much more transmissible than delta and the rapid spread of omicron would lead to a “staggering” number of COVID cases over the next few days. She delivered a series of dire warnings about the country’s health care system, although she added it was probably too early to tell how serious the scale of increasing infections across the world would turn out to be.

“The difficulty is that the growth of this virus, it has a doubling time which is shortening, i.e., it’s doubling faster, growing faster,” she said.

Governments across Europe are closely observing events unfolding in Britain for a sense of what may lie ahead for them as omicron spreads, and they are worried that reinfection rates from omicron are much higher than has been seen with earlier variants.

Restrictions and penalties

More countries are adopting restrictions. Italy this week required negative tests from vaccinated visitors to the country. Portugal has a similar measure in place. Many European countries have a virtual lockdown for the unvaccinated and are scrambling to increase vaccine booster programs. And more governments, including Germany’s, are proposing or considering mandatory vaccines.

Austria and Italy already plan to impose hefty fines on eligible people who do not get vaccinated.

People over 65 years old in France will be under effective lockdown from Wednesday, if they have not received a third vaccine booster dose.

France’s health pass will no longer be valid for the elderly who have not received a third dose, barring those who have not been boosted from visiting restaurants or cafes or taking intercity trains. They will also be prohibited from visiting cultural venues like cinemas or museums.

European Commission President Ursula von der Leyen warned Wednesday the European Union faces a double challenge, with a massive increase of delta cases in recent weeks and the threat of omicron looming. “We’re seeing an increasing number of people falling ill, a greater burden on hospitals and unfortunately, an increase in the number of deaths,” she told European Parliament lawmakers.

“And what I’m concerned about is that we now [are] seeing the new variant omicron on the horizon, which is apparently even more infectious,” she added.

But as governments go into overdrive, some epidemiologists and virologists are echoing Angelique Coetzee. Professor Tim Spector, the head of Genetic Epidemiology at King’s College, London, says the “majority of symptoms are just like a common cold, so we’re talking about headaches, sore throat, runny nose, fatigue, and things like sneezing.” He added: “So, things like fever and cough and loss of smell are now actually in the minority of the symptoms that we’re seeing.”

Earlier this week, the first major study published into the new variant also suggested illness from omicron is less severe than from delta. The study of 78,000 omicron cases in South Africa found the risk of hospitalization is 29% lower compared with the Wuhan strain, and 23% lower than with delta. Far fewer people have been needing intensive care. Just 5% of omicron cases have been admitted to intensive care units compared to 22% of delta patients, the study shows.

The data for the study was compiled by Discovery Health, South Africa’s largest private health insurer, and the South Africa Medical Research Council. It noted omicron can evade vaccines more than earlier strains, but the study found vaccines are still holding up well, although there were high numbers of breakthrough infections in people who had been vaccinated.

Vaccine effectiveness against infection dropped from 80% to 33%, according to the study, but offered 70% protection against hospital admission. Boosters may also mitigate the reduction in vaccine effectiveness, according to the study. Some European scientists have cautioned, though, against reading too much into the South African study, saying that South Africa’s population is much younger and that demographic differences could alter medical outcomes.

Source: Voice of America

US CDC: Omicron Now About 3% of All COVID-19 Cases

The White House COVID-19 Response team Wednesday said early data indicates the omicron coronavirus variant is spreading in the U.S., but current vaccine boosters appear to be effective in fighting it.

CDC Director Rochelle Walensky said the variant is in 36 U.S. states and accounts for 3% of all U.S. COVID-19 cases, though it is higher in some areas, such as New York and New Jersey, where it may account for as much 13% of cases.

Walensky said while the vast majority — 96% — of U.S. cases are still caused by the delta variant, she said early data show the omicron variant spreads faster than delta, with cases doubling in about two days.

Walensky, along with White House Chief Medical Adviser Anthony Fauci and COVID-19 Response coordinator Jeff Zients, cited data showing being fully vaccinated along with a booster shot is the best way to fight off the new variant.

“Our booster vaccine regimens work against omicron,” Fauci said. “At this point, there is no need for a variant-specific booster.”

Walensky cited recent data from U.S. nursing homes showing unvaccinated or fully vaccinated residents without boosters were 10 times more likely to contract COVID-19 than residents fully vaccinated with boosters. Fauci cited the most real-world studies showing boosters can increase anti-body protection against omicron by as much as 35 times.

Zients cited CDC statistics showing an unvaccinated person is eight times more likely to be hospitalized and 14 times more likely to die from COVID-19 than a fully vaccinated person. He said a new study from the Yale University of Public Health shows the U.S. vaccination program prevented 10.3 million hospitalizations and saved 1.1 million lives.

The COVID-19 response coordinator said 14 million people received booster shots in the first two weeks of December, with 26 million total shots in arms during the same period. In total, the team reports more than 200 million U.S. residents are now fully vaccinated, and more than 55 million have received booster shots.

Source: Voice of America